Weekly Analysts’ Ratings Updates for PetIQ (PETQ)

A number of firms have modified their ratings and price targets on shares of PetIQ (NASDAQ: PETQ) recently:

  • 5/23/2019 – PetIQ is now covered by analysts at Guggenheim. They set a “buy” rating and a $35.00 price target on the stock.
  • 5/17/2019 – PetIQ was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $33.00 price target on the stock. According to Zacks, “PetIQ, Inc. is a pet medication and wellness company. Its product consists of Rx Medications, OTC Medications and Supplies, Health and Wellness Products. The Company serves retail stores across the mass, club, grocery, pharmacy and e-commerce channels. PetIQ, Inc. is based in Eagle, United States. “
  • 5/14/2019 – PetIQ was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “PetIQ, Inc. is a pet medication and wellness company. Its product consists of Rx Medications, OTC Medications and Supplies, Health and Wellness Products. The Company serves retail stores across the mass, club, grocery, pharmacy and e-commerce channels. PetIQ, Inc. is based in Eagle, United States. “
  • 5/9/2019 – PetIQ was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 5/1/2019 – PetIQ was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

NASDAQ PETQ opened at $27.45 on Friday. The company has a quick ratio of 1.51, a current ratio of 2.89 and a debt-to-equity ratio of 0.38. PetIQ Inc has a 12-month low of $19.01 and a 12-month high of $43.93. The stock has a market cap of $774.12 million, a price-to-earnings ratio of 21.96, a price-to-earnings-growth ratio of 1.49 and a beta of 2.04.

PetIQ (NASDAQ:PETQ) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.19. PetIQ had a net margin of 0.51% and a return on equity of 9.47%. The business had revenue of $148.44 million during the quarter, compared to analyst estimates of $139.03 million. Sell-side analysts predict that PetIQ Inc will post 0.8 earnings per share for the current fiscal year.

In other PetIQ news, Director James Nathan Clarke purchased 31,031 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $28.12 per share, for a total transaction of $872,591.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Will Santana sold 20,000 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $25.63, for a total transaction of $512,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 120,000 shares of company stock valued at $3,524,800. Company insiders own 23.79% of the company’s stock.

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of PetIQ by 6,548.3% during the third quarter. JPMorgan Chase & Co. now owns 137,554 shares of the company’s stock valued at $5,407,000 after acquiring an additional 135,485 shares during the last quarter. Campbell Newman Asset Management Inc. raised its stake in shares of PetIQ by 3.8% during the first quarter. Campbell Newman Asset Management Inc. now owns 18,080 shares of the company’s stock valued at $568,000 after acquiring an additional 658 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of PetIQ by 226.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 95,881 shares of the company’s stock valued at $2,250,000 after acquiring an additional 66,498 shares during the last quarter. BCJ Capital Management LLC bought a new position in shares of PetIQ during the fourth quarter valued at about $235,000. Finally, Portolan Capital Management LLC raised its stake in shares of PetIQ by 51.6% during the fourth quarter. Portolan Capital Management LLC now owns 93,290 shares of the company’s stock valued at $2,190,000 after acquiring an additional 31,768 shares during the last quarter. 89.20% of the stock is owned by hedge funds and other institutional investors.

PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.

Featured Article: Why do company’s buyback their stock?

Receive News & Ratings for PetIQ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ Inc and related companies with MarketBeat.com's FREE daily email newsletter.